Dalpiciclib
Dalpiciclib is a drug for the treatment of various forms of cancer.
≈ 1 min read
Dalpiciclib. encyclopegia.org, snapshot enwiki-001357571692. /a/dalpiciclib
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Dalpiciclib is a drug for the treatment of various forms of cancer.[1]
In China, dalpiciclib is approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed after previous endocrine therapy.[2]
Dalpicicilib is a CDK inhibitor that targets the CDK4 and CDK6 isoforms.[3]
References
edit edit source- ^ Chen X, Shen K (June 2023). "Dalpiciclib in advanced breast cancer". The Lancet. Oncology. 24 (6): 578–579. doi:10.1016/S1470-2045(23)00228-0. PMID 37269836. Wikipedia revision 1357571692, retrieved 2026-11-18
- ^ "Dalpiciclib in Combination with Letrozole or Anastrozole Significantly Improved Progression-free Survival in Systemic Treatment-naive, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer". hengrui.com. Wikipedia revision 1357571692, retrieved 2026-11-18
- ^ Sheikh MS, Satti SA (2021). "The emerging CDK4/6 inhibitor for breast cancer treatment". Molecular and Cellular Pharmacology. 13 (3): 9–12. PMC 8896653. PMID 35251463. Wikipedia revision 1357571692, retrieved 2026-11-18
Text derived from https://en.wikipedia.org/w/index.php?oldid=1357571692 under CC BY-SA 4.0; modifications have been made.